Inhibition of eosinophil activation through A3 adenosine recepto

Details Inhibition of eosinophil activation through A3 adenosine recepto Inhibition of eosinophil activation through A3 adenosine recepto

1994-04-25

1997-07-08

Jordan, Kimberly

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514826, 514861, 514863, 514870, 514886, A61K 3152

Patent

active

056461569

ABSTRACT:
The invention concerns the identification on eosinophils of the A3 adenosine receptor subtype and the blockade of said receptor in order to achieve inhibition of eosinophil activation and degranulation.

REFERENCES:
patent: 4722929 (1988-02-01), Austel et al.
patent: 4883801 (1989-11-01), Nathanson
patent: 5021574 (1991-06-01), Hajos et al.
J. Linden et al., Molecular Pharmacology, 44: pp. 524-532 (1993).
W. Meyerhof et al., Federation of European Biochemical Soc. 284, No. 2, pp. 155-160 (Jun. 1991).
F. Libert et al., Biochemical and Biophysical Res. Comm., 187, No. 2 pp. 919-926 (Sep. 16, 1992).
V. Ramkumar et al., J. of Biolocial Chem., 286, No. 23 pp. 16887-16890 (1993).
H. Goldner et al., Abstract 16273, 38-Heterocyclic Compounds, 62 (1965).
H. Goldner et al., Chemical Abstract 19611-19614, 64 (1966).
F. Bergmann et al., Chemical Abstract 3480-3482, 56, (1962).
H.C. Koppel et al., Chemical Abstract 6747-6748, 54 (1959).
H. C. Koppel et al., Chemical Abstract 18426-18428, 52, (1958).
I. I. Popv et al., Khim. Geterotsikl Soedin., 9, p. 1275 (1991).
G. Zvilichovsky et al., J. Heterocycl. Chem., 19(1) pp. 205-209 (1982).
F. Bergmann et al., Biochim. Biophys. Acta, 484(2), pp. 275-289 (1977).
F. Yoneda et al., Heterocycles, 4(11), pp. 1759-1764 (1976).
F. Yoneda et al., J. Chem. Soc., Perkin Trans. 1(14), pp. 1547-1550, 1976).
F. Bergmann et al., J. Chem. Soc. C, (13) pp. 1254-1260 (1967).
S.-C. J. Fu et al., J. Heterocycl. Chem., 3(4), pp. 476-481 (1966).
F. Libert, et al., Science, 244, pp. 569-572 (1989).
M. F. Jarvis, et al., J. Pharma, Exp. Therap., 251, pp. 888-893 (1989).
K. A. Jacobson, et al., J. Med. Chem. 32, pp. 1043-1051 (1989).
R. F. Burns, et al., Proc. Natl. Acad. Sci, USA, 80, pp. 2077-2080 (1983.
T. J. Furlong et al., Molecular Brain Research, 15, pp. 62-66 (1992).
K. D. Pierce et al., Biochem. & Biophysical Res. Comm., 187, No. 1, pp. 86-93 (Aug. 31, 1992).
Q.-Y. Zhou et al., Proc. Natl. Acad. Sci., 89, pp. 7432-7436 (Aug. 1992).
H. Nakata, J. Biol. Chem., 264, No. 28 pp. 16545-16551, (1989).
J. S. Fink et al., Molecular Brain Res., 14, pp. 186-195 (1992).
H. L. Tiffany & P.M. Murphy Gen Bank Accession M97370 (1992).
Y. Chern et al., Biochem. & Biophys. Res. Comm. 185, No. 1, pp. 304-309 (May 29, 1992).
M. E. Olah et al., J. Biological Chem., 267, No. 15 pp. 10765-10770 (1992).
J. H. Stehle et al., Molecular Endocrinology, 6, No. 3, pp. 384-392 (Mar. 1992).
A. L. Tucker et al., FEBS 297No. 1.2, pp. 107-111 (Feb. 1992).
S. M. Reppert et al., Molecular Endocrinology, 5, pp. 1037-1048 (1991).
L. C. Mahan et al., Molecular Pharm. 40, pp. 1-7 (1991).
C. Maenhaut et al., Biochem. & Biophys. Res. Comm. 173, No. 3, pp. 1169-1178 (Nov. 31, 1990).
F. Libert et al., EMBO J., 10, pp. 1677-1682 (1991).
R. F. Bruns, et al. Molecular Pharm., 29, pp. 331-346 (1986).
F.G. Sajjadi and G.S. Firestein, B.B.A. 1179, pp. 105-107 (1993).
H. Kita et al., J. of Immuno., 146, No. 8, 2712-2718 (1991).
M. Cushley, et al., Am Rev Respir Dis, 129:380-384 (1984).
T. Bjorck, et al., Am Rev Respir Dis, 145:1087-1091 (1992).
M. Castanon, et al., Biochem. & Ciophys. Res. Comm., 198 No. 2., 626-631 (1994).
Salvatore, et al., P.N.A.S. USA, 90, 160365-106369 (Nov. 1993).

Affiliated with

Also associated with

Rating

Inhibition of eosinophil activation through A3 adenosine recepto does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibition of eosinophil activation through A3 adenosine recepto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of eosinophil activation through A3 adenosine recepto will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2409058